Insights Into Acute Lymphoblastic Leukemia (ALL)
Perspectives on the management of relapsed/refractory (R/R) ALL by community oncologists.
Faculty Chair
Ibrahim Aldoss, MD
City of Hope, Duarte, CA, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA
Faculty Chair
Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Insights Obtained From
- California, Oregon, Utah
Insights Obtained From
- Illinois, Ohio, Wisconsin
Insights Obtained From
- Florida, Illinois, Missouri, Tennessee, Texas, Wisconsin
Insights Obtained From
- New York, South Carolina
Insights Obtained From
- Massachusetts, New Jersey, New York, North Carolina, Pennsylvania
REPORT SNAPSHOT
- Management and treatment landscape of R/R ALL
- Updates in approved and emerging CAR T therapies
- Detailed insights and attendee takeaways
- ARS data
GEOGRAPHIC REPRESENTATION AND CONTENT DEVELOPMENT
- Data collection was accomplished through the use of audience response system questioning and moderated discussion
- The group of experts comprised 10–15 community oncologists representative of each region
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.